The new 2019 American college of rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for IgG4-related disease
https://doi.org/10.47360/1995-4484-2020-368-375
Abstract
This paper considers the new 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease, discusses essential differences with IgG4-RD comprehensive diagnostic criteria (Umehara H., 2011) and comments their potential use in clinical practice.
About the Author
E. V. Sokol
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Akiyama M, Takeuchi T. IgG4-Related Disease: Beyond Glucocorticoids. Drugs Aging. 2018;35(4):275-287. doi: 10.1007/s40266-018-0534-6
2. Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732-738. doi:10.1056/NEJM200103083441005
3. Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38(10):982-984. doi:10.1007/s00535-003-1175-y
4. Strehl JD, Hartmann A, Agaimy A. Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders. J Clin Pathol. 2011;64(3):237-43. doi: 10.1136/jcp.2010.085613
5. Carruthers MN, Khosroshahi A, Augustin T, et al. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis. 2015;74(1):14-8. doi: 10.1136/annrheumdis-2013-204907
6. Sokol E.V., Cherkasova M.V., Torgashina A.V. The diagnostic value of serum IgG4 for the diagnosis of IgG4- related disease: and is that so great? Sovremennaya revmatologiya =Modern Rheumatology Journal. 2019;13(1):52-57. (In Russ.). doi:10.14412/1996-7012-2019-1-52-57
7. Umehara H. Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21-30. doi: 10.1007/s10165-011-0571-z
8. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181- 92. doi: 10.1038/modpathol.2012.72
9. Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79(1):77-87. doi: 10.1136/annrheumdis-2019-216561
10. Wallace ZS, Zhang Y, Perugino CA, et al. Clinical phenotypes of IgG4-related disease: an analysis of two international crosssectional cohorts. Ann Rheum Dis. 2019;78(3):406-412. doi: 10.1136/annrheumdis-2018-214603
11. Sokol EV, Vasilyev VI, Palshina SG, et al. Clinical and laboratory characteristics of IgG4-realated disease and its diagnostic algorithm. Terapevticheskiy Arkhiv= Therapeutic Archive. 2019; 91 (5): 40–48. (In Russ.). doi: 10.26442/00403660.2019.05.000236
12. Wallace ZS, Deshpande V, Mattoo H, et al. IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients. Arthritis Rheumatol. 2015;67(9):2466-75. doi: 10.1002/art.39205
13. Lin W, Lu S, Chen H, et al. Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. Rheumatology (Oxford). 2015;54(11):1982-90. doi: 10.1093/rheumatology/kev203
14. Inoue D, Yoshida K, Yoneda N, et al. IgG4-related disease: dataset of 235 consecutive patients. Medicine (Baltimore). 2015;94(15):e680. doi: 10.1097/MD.0000000000000680
15. Wallace ZS, Wallace CJ, Lu N, et al. Association of IgG4-Related Disease With History of Malignancy. Arthritis Rheumatol. 2016;68(9):2283-9. doi: 10.1002/art.39773
16. Cheuk W, Yuen HK, Chan AC, et al. Ocular adnexal lymphoma associated with IgG4+ chronic sclerosing dacry-oadenitis: a previously undescribed complication of IgG4-related sclerosing disease. Am J Surg Pathol. 2008;32(8):1159-67. doi: 10.1097/PAS.0b013e31816148ad
17. Khosroshahi A, Wallace ZS, Crowe JL, et al. Second International Symposium on IgG4-Related Disease International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheumatol. 2015;67(7):1688-99. doi: 10.1002/art.39132
18. Stone JH, Brito-Zerón P, Bosch X, Ramos-Casals M. Diagnostic Approach to the Complexity of IgG4-Related Disease. Mayo Clin Proc. 2015;90(7):927-39. doi:10.1016/j.mayocp.2015.03.020
19. Sokol E.V., Vasilyev V.I. Treatment of IgG4-related disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):352-360. (In Russ.). doi:10.14412/1995-4484-2016-352-360
20. Sokol E, Vasilyev V, Palshina S. Can cyclophosphamide be used as a first line therapy in IgG4-RD without oral glucocorticoids? [архив] Ссылка активна на 27.04.2020 http://www.internationalsymposium.net/igG4/wp-content/uploads/2017/02/P-35Evgeniya Sokol.pdf
21. Nasonov EL, Beketova TV, Ananyeva LP, et al. Prospects for anti-B-cell therapy in immune-inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2019; 57:1-40. (In Russ.). doi:10.14412/1995-4484-2019-3-40
22. Beketova TV, Arseniev EV, Kokosadze NV. Clinical and immunological variants of ANCA-associated systemic vasculitis: a look at the phenomenon of IgG4 overproduction. Literature review and own observation. Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. (In Russ.). Link active on 27.04.2020 https://rsp.ima-press.net/rsp/article/view/2827.
23. Erden A, Bolek EC, Yardimci KG, et al. Do ANCA-associated vasculitis and IgG4-related disease really overlap or not? Int J Rheum Dis. 2019;22(10):1926-1932. doi: 10.1111/1756-185X.13693
24. Vasiliev VI, Sokol EV, Sedishev SH et al. Differential diagnosis of rheumatic and oncohematological diseases affecting the cavity and paranasal sinuses. Terapevticheskiy Arkhiv= Therapeutic Archive Journal 2014; 86 (5): 62–72. (In Russ.)
25. Morgan WS, Castleman BA. clinicopathologic study of Mikulicz’s disease. The American journal of pathology.1953;29(3): 471–503
26. Simonova MV, Vasiliev VI, Kornilova NN Differential diagnosis of Mikulich’s disease and Sjogren’s disease. Dentistry. 1988;3:71-73. (in Russ)
27. Yamamoto M, Harada S, Ohara M, et al. Clinical and pathological differences between Mikulicz’s disease and Sjögren’s syndrome. Rheumatology (Oxford). 2005;44(2):227-234. doi:10.1093/rheumatology/keh447
28. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9-16. doi: 10.1136/annrheumdis-2016-210571
29. Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical Guidelines]. Moscow: GEOTARMedia; 2017. 464 p. (In Russ.)
30. Sokol E. Rodionova E, Vasilyev V, et al. Major salivary glands ultrasonography in differential diagnosis of IgG4-related disease and primary Sjogren’s syndrome. Ann Rheum Dis. 2018;77(Suppl):A1147. doi: 10.1136/annrheumdis-2018-eular.5413
31. Yamamoto M, Takahashi H, Shinomura Y. Are Sjögren’s syndrome and IgG4-related disease able to coexist? Modern Rheumatology. 2015 ;25(6):970-971. doi: 10.3109/14397595.2014.948950
32. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8- negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646-1657. doi: 10.1182/blood-2016-10-746933.
33. Sato Y, Kojima M, Takata K, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman’s disease. Mod Pathol. 2009 ;22(4):589- 99. doi: 10.1038/modpathol.2009.17
34. Sato Y, Kojima M, Takata K, et al. Multicentric Castleman’s disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases. J Clin Pathol. 2010;63(12):1084-9. doi: 10.1136/jcp.2010.082958
35. Wallace ZS, Sato Y, Okazaki K, et al. Multi-Organ Inflammatory Condition with Features of Idiopathic Multicentric Castleman’s Disease and IgG4-Related Disease: An Unrecognized Mimicker of IgG4-RD.Arthritis Rheumatol. 2017; 69 (suppl 10).
36. Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood.2014;124:483-492. doi: 10.1182/blood-2014-03- 561381
37. Vasiliev VI, Sokol EV, Kokosadze NV et al. Differential diagnosis of Erdheim-Chester disease and IgG4-related disease. Terapevticheskiy Arkhiv= Therapeutic Archive Journal. 2016; 88 (5): 70–76. (In Russ.). doi: 10.17116/terarkh201688570-76
38. Okazaki K, Kawa S, Kamisawa T, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 I. Concept and diagnosis of autoimmune pancreatitis. J Gastroenterol. 2014;49(4):567-88. doi: 10.1007/s00535-014-0942-2
39. Tsen A, Alishahi Y, Rosenkranz L. Autoimmune Pancreatitis and Inflammatory Bowel Disease: An Updated Review. J Clin Gastroenterol. 2017;51(3):208-214. doi: 10.1097/MCG.0000000000000737
40. Li Y, Nishihara E, Kakudo K, et al. Hashimoto thyroiditis: old concepts and new insights. Current opinion in rheumatology. 2011; 23 (1): 102-107. doi: 10.1097/bor.0b013e328341378c
41. Li Y, Bai Y, Liu Z, et al. Immunohistochemistry of IgG4 can help subclassify Hashimoto’s autoimmune thyroiditis. Pathol Int. 2009;59(9):636-641. doi:10.1111/j.1440-1827.2009.02419.x
42. Yu KH, Chan TM, Tsai PH, et al. Diagnostic Performance of Serum IgG4 Levels in Patients With IgG4-Related Disease. Medicine (Baltimore). 2015;94(41):e1707. doi: 10.1097/MD.0000000000001707
43. Sokol EV. IgG4-related disease: what we know 20 years later. Terapevticheskiy Arkhiv= Therapeutic Archive Journal 2020; 92 (5):104-109 (in Russ). doi: 10.26442/00403660.2020.05.000632
44. Inoue D, Zen Y, Abo H, et al. Immunoglobulin G4-related lung disease: CT findings with pathologic correlations. Radiology. 2009;251(1):260-70. doi: 10.1148/radiol.2511080965
45. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352-8. doi: 10.1097/MPA.0b013e3182142fd2
46. Hamano H, Arakura N, Muraki T, Ozaki Y, Kiyosawa K, Kawa S. Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis. J Gastroenterol. 2006;41(12):1197-1205. doi:10.1007/s00535-006-1908-9
47. Kawano M, Saeki T, Nakashima H. IgG4-related kidney disease and retroperitoneal fibrosis: An update. Mod Rheumatol. 2019;29(2):231-239. doi: 10.1080/14397595.2018.1554321
48. Ormond JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol. 1948;59(6):1072-9
49. Khosroshahi A, Carruthers MN, Stone JH, et al. Rethinking Ormond’s disease: “idiopathic” retroperitoneal fibrosis in the era of IgG4-related disease. Medicine (Baltimore). 2013;92(2):82-91. doi: 10.1097/MD.0b013e318289610f
Review
For citations:
Sokol E.V. The new 2019 American college of rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for IgG4-related disease. Rheumatology Science and Practice. 2020;58(4):368-375. (In Russ.) https://doi.org/10.47360/1995-4484-2020-368-375
Views:
1213
Email this article 